Quality of life and psychological impact in the photodermatoses: a systematic review.
Journal
The British journal of dermatology
ISSN: 1365-2133
Titre abrégé: Br J Dermatol
Pays: England
ID NLM: 0004041
Informations de publication
Date de publication:
05 2020
05 2020
Historique:
pubmed:
7
7
2019
medline:
15
5
2021
entrez:
7
7
2019
Statut:
ppublish
Résumé
The photodermatoses affect large proportions of the population but their impact on quality of life (QoL) and psychological health has not been reviewed. Several tools are available to evaluate QoL and psychological impacts. To systematically review current literature to identify tools used to assess QoL and psychological impacts in patients with photodermatoses, and to summarize the reported findings. A systematic search of PubMed, OVID Medline, PsycInfo and CINAHL was performed for articles investigating QoL and/or psychological impact in patients with photodermatoses, published between 1960 and September 2018. Twenty studies were included: 19 incorporated QoL assessment while three evaluated psychological morbidity. Six QoL tools were found to be used: Dermatology Life Quality Index (DLQI), Children's DLQI, Family DLQI, Skindex (16- and 29-item versions), Erythropoietic Protoporphyria Quality of Life (EPP-QoL) and EuroQol. Between 31% and 39% of photosensitive patients reported a very large impact on QoL (DLQI > 10). Employment and education, social and leisure activities, and clothing choices were particularly affected. Only one tool was specifically designed for a photodermatosis (EPP-QoL). Four tools were used to evaluate psychological impact: the Hospital Anxiety and Depression Scale, Fear of Negative Evaluation, brief COPE and Illness Perception Questionnaire-Revised. Levels of anxiety and depression were approximately double British population data. Patients with facial involvement, female gender and younger age at onset showed more psychological morbidity. Several tools have been used to assess QoL in the photodermatoses, and confirm substantial impact on QoL. Development of specific, validated QoL measures would address their unique impacts. Research delineating their psychological comorbidity is sparse and requires further exploration. What's already known about this topic? The photodermatoses negatively impact quality of life (QoL) and cause psychological distress, but no reviews of this area appear in the literature. What does this study add? Few studies have explored the psychological and social impacts of the photodermatoses. There are no fully validated QoL tools specific to the photodermatoses. Around one-third of adult and child patients with photosensitivity experience very or extremely large impact on QoL, with particular effect on clothing choices, employment and social and leisure activities. Studies suggest anxiety and depression levels in these patients are around double those in the U.K. general population. More attention is required on these 'hidden' conditions.
Sections du résumé
BACKGROUND
The photodermatoses affect large proportions of the population but their impact on quality of life (QoL) and psychological health has not been reviewed. Several tools are available to evaluate QoL and psychological impacts.
OBJECTIVES
To systematically review current literature to identify tools used to assess QoL and psychological impacts in patients with photodermatoses, and to summarize the reported findings.
METHODS
A systematic search of PubMed, OVID Medline, PsycInfo and CINAHL was performed for articles investigating QoL and/or psychological impact in patients with photodermatoses, published between 1960 and September 2018.
RESULTS
Twenty studies were included: 19 incorporated QoL assessment while three evaluated psychological morbidity. Six QoL tools were found to be used: Dermatology Life Quality Index (DLQI), Children's DLQI, Family DLQI, Skindex (16- and 29-item versions), Erythropoietic Protoporphyria Quality of Life (EPP-QoL) and EuroQol. Between 31% and 39% of photosensitive patients reported a very large impact on QoL (DLQI > 10). Employment and education, social and leisure activities, and clothing choices were particularly affected. Only one tool was specifically designed for a photodermatosis (EPP-QoL). Four tools were used to evaluate psychological impact: the Hospital Anxiety and Depression Scale, Fear of Negative Evaluation, brief COPE and Illness Perception Questionnaire-Revised. Levels of anxiety and depression were approximately double British population data. Patients with facial involvement, female gender and younger age at onset showed more psychological morbidity.
CONCLUSIONS
Several tools have been used to assess QoL in the photodermatoses, and confirm substantial impact on QoL. Development of specific, validated QoL measures would address their unique impacts. Research delineating their psychological comorbidity is sparse and requires further exploration. What's already known about this topic? The photodermatoses negatively impact quality of life (QoL) and cause psychological distress, but no reviews of this area appear in the literature. What does this study add? Few studies have explored the psychological and social impacts of the photodermatoses. There are no fully validated QoL tools specific to the photodermatoses. Around one-third of adult and child patients with photosensitivity experience very or extremely large impact on QoL, with particular effect on clothing choices, employment and social and leisure activities. Studies suggest anxiety and depression levels in these patients are around double those in the U.K. general population. More attention is required on these 'hidden' conditions.
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1092-1102Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2019 British Association of Dermatologists.
Références
Choi D, Kannan S, Lim HW. Evaluation of patients with photodermatoses. Dermatol Clin 2014; 32:267-75.
Hart PH, Norval M, Byrne SN, Rhodes LE. Exposure to ultraviolet radiation in the modulation of human diseases. Annu Rev Pathol 2019; 14:55-81.
Rhodes LE, Bock M, Janssens AS et al. Polymorphic light eruption occurs in 18% of Europeans and does not show higher prevalence with increasing latitude: multicenter survey of 6,895 individuals residing from the Mediterranean to Scandinavia. J Invest Dermatol 2010; 130:626-8.
Holme SA, Anstey AV, Finlay AY et al. Erythropoietic protoporphyria in the U.K.: clinical features and effect on quality of life. Br J Dermatol 2006; 155:574-81.
Beattie PE, Dawe RS, Ibbotson SH et al. Characteristics and prognosis of idiopathic solar urticaria: a cohort of 87 cases. Arch Dermatol 2003; 139:1149-54.
Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) - a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19:210-16.
Harlow D, Poyner T, Finlay AY et al. Impaired quality of life of adults with skin disease in primary care. Br J Dermatol 2000; 143:979-82.
Kyle SD, Morgan K, Espie CA. Insomnia and health-related quality of life. Sleep Med Rev 2010; 14:69-82.
Gupta MA, Gupta AK. Depression and suicidal ideation in dermatology patients with acne, alopecia areata, atopic dermatitis and psoriasis. Br J Dermatol 1998; 139:846-50.
Gupta MA, Gupta AK. Psychiatric and psychological co-morbidity in patients with dermatologic disorders: epidemiology and management. Am J Clin Dermatol 2003; 4:833-42.
Picardi A, Abeni D, Melchi CF et al. Psychiatric morbidity in dermatological outpatients: an issue to be recognized. Br J Dermatol 2000; 143:983-91.
Richards HL, Fortune DG, Griffiths CE et al. The contribution of perceptions of stigmatisation to disability in patients with psoriasis. J Psychosom Res 2001; 50:11-15.
Fortune DG, Main CJ, O'Sullivan TM et al. Quality of life in patients with psoriasis: the contribution of clinical variables and psoriasis-specific stress. Br J Dermatol 1997; 137:755-60.
Wittkowski A, Richards HL, Griffiths CE et al. The impact of psychological and clinical factors on quality of life in individuals with atopic dermatitis. J Psychosom Res 2004; 57:195-200.
Stafford R, Farrar MD, Kift R et al. The impact of photosensitivity disorders on aspects of lifestyle. Br J Dermatol 2010; 163:817-22.
Rizwan M, Haylett AK, Richards HL et al. Impact of photosensitivity disorders on the life quality of children. Photodermatol Photoimmunol Photomed 2012; 28:290-2.
National Heart Lung and Blood Institute. Study quality assessment tools. Available at: https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools (last accessed 7 August 2019).
Foering K, Goreshi R, Klein R et al. Prevalence of self-report photosensitivity in cutaneous lupus erythematosus. J Am Acad Dermatol 2012; 66:220-8.
Hawkins DM, Eide MJ, Lim HW. Perception of xeroderma pigmentosum support group members of xeroderma pigmentosum lifestyle impact. Photodermatol Photoimmunol Photomed 2012; 28:338-9.
Huggins RH, Leithauser LA, Eide MJ et al. Quality of life assessment and disease experience of patient members of a web-based hydroa vacciniforme support group. Photodermatol Photoimmunol Photomed 2009; 25:209-15.
Jong CT, Finlay AY, Pearse AD et al. The quality of life of 790 patients with photodermatoses. Br J Dermatol 2008; 159:192-7.
Katugampola RP, Badminton MN, Finlay AY et al. Congenital erythropoietic porphyria: a single-observer clinical study of 29 cases. Br J Dermatol 2012; 167:901-13.
Kil EH, DeLeo VA. A survey examination of patients with hydroa vacciniforme. Cutis 2011; 88:245-53.
Richards HL, Ling TC, Evangelou G et al. Psychologic distress in polymorphous light eruption and its relationship to patients’ beliefs about their condition. J Am Acad Dermatol 2007; 56:426-31.
Richards HL, Ling TC, Evangelou G et al. Evidence of high levels of anxiety and depression in polymorphic light eruption and their association with clinical and demographic variables. Br J Dermatol 2008; 159:439-44.
Rizwan M, Reddick CL, Bundy C et al. Photodermatoses: environmentally induced conditions with high psychological impact. Photochem Photobiol Sci 2013; 12:182-9.
Biolcati G, Marchesini E, Sorge F et al. Long-term observational study of afamelanotide in 115 patients with erythropoietic protoporphyria. Br J Dermatol 2015; 172:1601-12.
Haylett AK, Koumaki D, Rhodes LE. Solar urticaria in 145 patients: assessment of action spectra and impact on quality of life in adults and children. Photodermatol Photoimmunol Photomed 2018; 34:262-8.
Ishiguro M, Hashizume H, Ikeda T et al. Evaluation of the quality of life of lupus erythematosus patients with cutaneous lesions in Japan. Lupus 2014; 23:93-101.
Ling TC, Richards HL, Janssens AS et al. Seasonal and latitudinal impact of polymorphic light eruption on quality of life. J Invest Dermatol 2006; 126:1648-51.
Macfarlane L, Hawkey S, Naasan H et al. Characteristics of actinic prurigo in Scotland: 24 cases seen between 2001 and 2015. Br J Dermatol 2016; 174:1411-14.
Franken SM, Genders RE, de Gruijl FR et al. Skin hardening effect in patients with polymorphic light eruption: comparison of UVB hardening in hospital with a novel home UV-hardening device. J Eur Acad Dermatol Venereol 2013; 27:67-72.
Huang C, Yan S, Ren J et al. A quantitative assessment of the effects of formal sun protection education on photosensitive patients. Photodermatol Photoimmunol Photomed 2013; 29:261-5.
Langendonk JG, Balwani M, Anderson KE et al. Afamelanotide for erythropoietic protoporphyria. N Engl J Med 2015; 373:48-59.
Hongbo Y, Thomas CL, Harrison MA et al. Translating the science of quality of life into practice: what do Dermatology Life Quality Index scores mean? J Invest Dermatol 2005; 125:659-64.
Basra MK, Fenech R, Gatt RM et al. The Dermatology Life Quality Index 1994-2007: a comprehensive review of validation data and clinical results. Br J Dermatol 2008; 159:997-1035.
Lewis-Jones MS, Finlay AY. The Children's Dermatology Life Quality Index (CDLQI): initial validation and practical use. Br J Dermatol 1995; 132:942-9.
Finlay AY, Basra MK. DLQI and CDLQI scores should not be combined. Br J Dermatol 2012; 167:453-4.
Salek MS, Jung S, Brincat-Ruffini LA et al. Clinical experience and psychometric properties of the Children's Dermatology Life Quality Index (CDLQI), 1995-2012. Br J Dermatol 2013; 169:734-59.
Basra MK, Sue-Ho R, Finlay AY. The Family Dermatology Life Quality Index: measuring the secondary impact of skin disease. Br J Dermatol 2007; 156:528-38.
Chren MM, Lasek RJ, Quinn LM et al. Skindex, a quality-of-life measure for patients with skin disease: reliability, validity, and responsiveness. J Invest Dermatol 1996; 107:707-13.
Chren MM. The Skindex instruments to measure the effects of skin disease on quality of life. Dermatol Clin 2012; 30:231-6.
Chren MM, Lasek RJ, Sahay AP et al. Measurement properties of Skindex-16: a brief quality-of-life measure for patients with skin diseases. J Cutan Med Surg 2001; 5:105-10.
EuroQol Group. EuroQol - a new facility for the measurement of health-related quality of life. Health Policy 1990; 16:199-208.
Payakachat N, Ali MM, Tilford JM. Can the EQ-5D detect meaningful change? A systematic review. Pharmacoeconomics 2015; 33:1137-54.
Bjelland I, Dahl AA, Haug TT et al. The validity of the Hospital Anxiety and Depression Scale. An updated literature review. J Psychosom Res 2002; 52:69-77.
Nelson PA, Kane K, Pearce CJ et al. ‘New to me’: changing patient understanding of psoriasis and identifying mechanisms of change. The Pso Well® patient materials mixed-methods feasibility study. Br J Dermatol 2017; 177:758-70.
Watson D, Friend R. Measurement of social-evaluative anxiety. J Consult Clin Psychol 1969; 33:448-57.
Carver CS. You want to measure coping but your protocol's too long: consider the brief COPE. Int J Behav Med 1997; 4:92-100.
Monzani D, Steca P, Greco A et al. The situational version of the brief COPE: dimensionality and relationships with goal-related variables. Eur J Psychol 2015; 11:295-310.
Moss-Morris R, Weinman J, Petrie K et al. The Revised Illness Perception Questionnaire (IPQ-R). Psychol Health 2002; 17:1-16.
Basra MK, Edmunds O, Salek MS et al. Measurement of family impact of skin disease: further validation of the Family Dermatology Life Quality Index (FDLQI). J Eur Acad Dermatol Venereol 2008; 22:813-21.
Lundberg L, Johannesson M, Silverdahl M et al. Health-related quality of life in patients with psoriasis and atopic dermatitis measured with SF-36, DLQI and a subjective measure of disease activity. Acta Derm Venereol 2000; 80:430-4.
Kurwa HA, Finlay AY. Dermatology in-patient management greatly improves life quality. Br J Dermatol 1995; 133:575-8.
Shum KW, Lawton S, Williams HC et al. The British Association of Dermatologists audit of atopic eczema management in secondary care. Phase 3: audit of service outcome. Br J Dermatol 2000; 142:721-7.
Holm JG, Agner T, Clausen ML et al. Quality of life and disease severity in patients with atopic dermatitis. J Eur Acad Dermatol Venereol 2016; 30:1760-7.
Beattie PE, Lewis-Jones MS. A comparative study of impairment of quality of life in children with skin disease and children with other chronic childhood diseases. Br J Dermatol 2006; 155:145-51.
Olsen JR, Gallacher J, Finlay AY et al. Quality of life impact of childhood skin conditions measured using the Children's Dermatology Life Quality Index (CDLQI): a meta-analysis. Br J Dermatol 2016; 174:853-61.
Tamási B, Brodszky V, Péntek M et al. Validity of the EQ-5D in patients with pemphigus vulgaris and pemphigus foliaceus. Br J Dermatol 2019; 180:802-9.
Janssen B, Szende A. Population norms for the EQ-5D. In: Self-Reported Population Health: An International Perspective Based on EQ-5D (Szende A, Janssen B, Cabases J, eds). Dordrecht: Springer Netherlands, 2014; 19-30.
Crawford JR, Henry JD, Crombie C et al. Normative data for the HADS from a large non-clinical sample. Br J Clin Psychol 2001; 40:429-34.
Both H, Essink-Bot ML, Busschbach J et al. Critical review of generic and dermatology-specific health-related quality of life instruments. J Invest Dermatol 2007; 127:2726-39.
Finlay AY. Broader concepts of quality of life measurement, encompassing validation. J Eur Acad Dermatol Venereol 2017; 31:1254-9.
Finlay AY, Basra MKA, Piguet V et al. Dermatology Life Quality Index (DLQI): a paradigm shift to patient-centered outcomes. J Invest Dermatol 2012; 132:2464-5.
van Cranenburgh OD, Prinsen CA, Sprangers MA et al. Health-related quality-of-life assessment in dermatologic practice: relevance and application. Dermatol Clin 2012; 30:323-32.
Ali FM, Kay R, Finlay AY et al. Mapping of the DLQI scores to EQ-5D utility values using ordinal logistic regression. Qual Life Res 2017; 26:3025-34.